Evaluation of the effect of Tofacitinib in covid-19 patients
Phase 3
Recruiting
- Conditions
- Coronavirus disease (COVID-19).An emergency ICD-10 code of ‘U07.1 COVID-19, virus identified’ is assigned to a disease diagnosis of COVID-19 confirmed by laboratory testing,An emergency ICD-10 code of ‘U07.2 COVID-19, virus not identified’ is assigned to a clinical or epidemiological dU07.1.2
- Registration Number
- IRCT20200531047619N1
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Severe illness (respiratory rate above 30 per minute, heart rate above 120 per minute and per cent reduction in peripheral oxygen saturation to less than 93%)
Patients resistant to existing treatments
Exclusion Criteria
Bacterial infection is positive for the patient or procalcitonin is positive
The patient may have hepatitis B or hepatitis C or HIV
The patient has pulmonary embolism or intravascular thrombosis
The patient has active and inactive tuberculosis
The patient has diverticulitis and peptic ulcer
Leukocytes count less than 3500 cells / mm and hemoglobin less than 9 g / dL and neutrophils less than 1000 cells / mm3
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Oxygen saturation level. Timepoint: Daily. Method of measurement: Pulse oximetry.;Rate of breaths. Timepoint: Daily. Method of measurement: Number per minute.;Heart Rate. Timepoint: Daily. Method of measurement: Number per minute.;Level of consciousness. Timepoint: Daily. Method of measurement: GCS, Glasgow Coma Scale.
- Secondary Outcome Measures
Name Time Method